Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment

Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment

Source: 
BioSpace
snippet: 

Shares of Intercept Pharmaceuticals have exploded this morning after the company announced positive news from its Phase III nonalcoholic steatohepatitis (NASH) trial. The stock has shot up more than 20 percent in premarket trading to $133 per share as investors see the potential for the first approved NASH treatment in the U.S.